Our goal: better-informed treatment and follow-up.
For investors
Oncology is becoming data-rich. Clinical decisions are still data-poor.
EvoClin is building the infrastructure and proprietary AI to turn fragmented clinical and molecular data into patient-level foresight.
The market shift
More patients. More sequencing. More data hospitals cannot yet use.
Molecular profiling is moving into routine oncology, while clinical and genomic evidence remains fragmented across reports and disconnected systems.
Italy: up to €22bn/year in potential healthcare savings from AI. More time and resources for care. Anaao Assomed
Our goal: less manual work and clearer priorities.
Our goal: better use of capacity and clinical resources.
Commercial path
From workflow utility to predictive oncology at scale.
The initial opportunity is reducing manual data work within existing hospital workflows. A connected patient view creates the foundation for clinical and operational insight, with our patented AI models providing the scientific basis for future predictive applications.
Development is progressing and pilot collaborations are getting started. Clinical validation must precede deployment.
Early developmentPilots startingPlanned validationFuture deployment
Investor information